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a scale of 0 to 100. Signiﬁcative difference was observed
between M and W for the global handicap score 20.73
vs 16,95 p < 0,002. Two groups were identiﬁed: ﬂare-up
of psoriasis (84%), psoriasis not in ﬂare-up (12%)—no
answers (4%)- Psoriasis had a greater affect on patients
with episode: PDI score = 20,24 (sd 17,52) than the
patient without episode PDI score = 8.98 (sd 11,34). This
difference was signiﬁcant p < 0.00001. CONCLUSION:
These results highlight the value of appropriate and rele-
vant psychological and medical environment for patient
suffering from psoriasis.
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OBJECTIVE: To evaluate the effect of psoriasis on
quality of life of patients and DS in France. To highlight
a relation between DS and quality of life for patients suf-
fering from psoriasis. METHOD: Seven hundred ﬁfty
anonymous questionnaires (comprised two scales: the
Psoriasis Disability Index [PDI] and the Center for Epi-
demiologic Studies—Depression scale [CES-D] were sent,
via a Psoriasis Patient Support Group (APLCP). The CES-
D, a short self-report scale composed of 20 items is a
questionnaire designed to measure DS in the general pop-
ulation. The CES-D is widely used in epidemiological
surveys on large populations. The PDI is a questionnaire
speciﬁc for psoriasis patients. RESULTS: 297 question-
naires were returned (June 2002): response rate 39.6%.
The sex ratio Men (M)/Women (W) was 47/53. Mean
age: 48.8 years. Mean age of diagnosis: 26.3 years. The
average to the total PDI score was 10.3 (s.d: 7.7 rank 0
to 39) i.e 22.8 (sd: 17.10) when reported to a scale of 0
to 100. Signiﬁcant difference was observed between W
and M for the global handicap score 24.53 vs 19.87 p <
0.02. Two groups were identiﬁed: ﬂare-up of psoriasis
(49.5%), psoriasis not in ﬂare-up (48%)—no answers
(2.5%)—Psoriasis had a greater affect on patients with
episode: PDI score = 24.9 (s.d: 17.02) than patient
without episode: PDI score = 20.27 (s.d: 16.91). This dif-
ference was signiﬁcant (p < 0.05). In the studied popula-
tion, 44.6% of the patients reported DS (CES-D+)
whereas 55.4% did not (CES-D-). In CES-D+ patients the
PDI score = 30.98 (sd: 18.28) was higher than the score
in CES-D-patients: PDI score = 16.43 (sd: 13.97). This
difference was signiﬁcant (p < 2.10–11). CONCLUSION:
Patients in a current ﬂare-up of psoriasis are more
affected and feel more disabled in their daily life (higher
disability score and higher frequency of DS) compared to
patients without episode. Patients with DS (CES-D+),
reported a higher impact of their psoriasis on their quality
of life (PDI score 30.98 versus 16.43).
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The Dermatology Life Quality Index (DLQI) was
designed to be used with different types of dermatologic
pathologies instead of being directed at a single condi-
tion such as psoriasis or acne. Although a reasonable
approach, this broader measurement model may not be
appropriate for conditions such as chronic idiopathic
urticaria (CIU) that, unlike some other chronic skin con-
ditions, are subject to daily or weekly ﬂuctuations.
OBJECTIVES: This validation study tested the reliability,
structural validity, and construct validity of the DLQI in
two samples of CIU patients obtained from two large
identical multicenter, double-blind, randomized, placebo-
controlled, parallel studies. METHODS: Patients
recorded daily signs and symptoms (# of wheals and 
pruritus severity) on a daily basis, and completed the
DLQI during three clinic visits (approximately 2 weeks
apart); investigators also assessed CIU severity.
RESULTS: The DLQI means and standard deviations
indicated relatively symmetrical distributions free from
serious ceiling or ﬂoor effects, and alpha coefﬁcients indi-
cated an acceptable level of reliability in the two samples.
The exploratory factor analysis suggested that the six cat-
egories of items did not deﬁne different factors and sup-
ported the unidimensionality of the scale. In a formal test
of the structural validity for a single-factor model, con-
ﬁrmatory factor analysis supported either a one or two-
factor model, with the correlations from the two-factor
model indicating that the total score of all items is inter-
pretable as a global score. Item response analyses showed
that most items were able to distinguish people with 
low versus high impairment at the appropriate ends of 
the continuum demonstrating content validity. Finally,
changes in DLQI scores were related to changes in inves-
tigator and patient-assessed symptoms of urticaria, pro-
viding evidence of construct validity. CONCLUSION:
These results support the DLQI as a valid instrument for
the measurement of CIU related quality of life.
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OBJECTIVES: In spite of the common occurrence of der-
matological problems there are virtually no population-
based studies on the impact of skin diseases in the
